Next Article in Journal
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
Next Article in Special Issue
Metastatic Neuroendocrine Neoplasms of Unknown Primary: Clues from Pathology Workup
Previous Article in Journal
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
Previous Article in Special Issue
Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance
 
 
Article

Article Versions Notes

Cancers 2022, 14(4), 1038; https://doi.org/10.3390/cancers14041038
Action Date Notes Link
article xml file uploaded 18 February 2022 10:58 CET Original file -
article xml uploaded. 18 February 2022 10:58 CET Update https://www.mdpi.com/2072-6694/14/4/1038/xml
article pdf uploaded. 18 February 2022 10:58 CET Version of Record https://www.mdpi.com/2072-6694/14/4/1038/pdf
article supplementary file uploaded. 18 February 2022 10:58 CET - https://www.mdpi.com/2072-6694/14/4/1038#supplementary
article html file updated 18 February 2022 11:00 CET Original file -
article html file updated 31 July 2022 22:22 CEST Update https://www.mdpi.com/2072-6694/14/4/1038/html
Back to TopTop